Trials / Recruiting
RecruitingNCT07249788
Resmiterom Efficacy & Safety in Patients With MASH
Clinical Evaluation of Safety and Efficacy of Resmiterom in Patients With MASH (Metabolic Dysfunction-Associated Steato-Hepatitis) A Prospective, Open-label, Interventional Study
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 165 (estimated)
- Sponsor
- Nabiqasim Industries (Pvt) Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Resmetirom | 1st FDA approved MASH therapy |
Timeline
- Start date
- 2025-10-17
- Primary completion
- 2026-10-16
- Completion
- 2026-12-31
- First posted
- 2025-11-25
- Last updated
- 2025-12-03
Locations
1 site across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT07249788. Inclusion in this directory is not an endorsement.